RIGL

Company Overview — What Does RIGEL PHARMACEUTICALS INC Do?

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. RIGEL PHARMACEUTICALS INC (RIGL) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Raul R. Rodriguez and employs approximately 160 people. With a market capitalization of $508M, RIGL is one of the notable companies in the Healthcare sector.

RIGEL PHARMACEUTICALS INC (RIGL) Stock Rating — Reduce (April 2026)

As of April 2026, RIGEL PHARMACEUTICALS INC receives a Reduce rating with a composite score of 41.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RIGL ranks #3,266 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, RIGEL PHARMACEUTICALS INC ranks #495 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RIGL Stock Price and 52-Week Range

RIGEL PHARMACEUTICALS INC (RIGL) currently trades at $30.51. The 52-week high for RIGL is $52.24, which means the stock is currently trading -41.6% from its annual peak. The 52-week low is $15.50, putting the stock 96.8% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is RIGL Overvalued or Undervalued? — Valuation Analysis

RIGEL PHARMACEUTICALS INC (RIGL) carries a value factor score of 80/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 4.77x, compared to the Healthcare sector average of 23.63x — a discount of 80%. The price-to-book ratio stands at 1.36x, versus the sector average of 2.75x. The price-to-sales ratio is 1.90x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, RIGL trades at 5.01x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, RIGEL PHARMACEUTICALS INC appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

RIGEL PHARMACEUTICALS INC Profitability — ROE, Margins, and Quality Score

RIGEL PHARMACEUTICALS INC (RIGL) earns a quality factor score of 38/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 28.4%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 21.7% versus the sector average of -33.1%.

On a margin basis, RIGEL PHARMACEUTICALS INC reports gross margins of 91.5%, compared to 71.5% for the sector. The operating margin is 37.6% (sector: -66.1%). Net profit margin stands at 35.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 88.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RIGL Debt, Balance Sheet, and Financial Health

RIGEL PHARMACEUTICALS INC has a debt-to-equity ratio of 13.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.42x, indicating strong short-term liquidity. Total debt on the balance sheet is $53M. Cash and equivalents stand at $49M.

RIGL has a beta of 0.86, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for RIGEL PHARMACEUTICALS INC is 40/100, reflecting average volatility within the normal range for its sector.

RIGEL PHARMACEUTICALS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, RIGEL PHARMACEUTICALS INC reported revenue of $280M and earnings per share (EPS) of $20.40. Net income for the quarter was $111M. Gross margin was 91.5%. Operating income came in at $116M.

In FY 2025, RIGEL PHARMACEUTICALS INC reported revenue of $294M and earnings per share (EPS) of $20.40. Net income for the quarter was $367M. Gross margin was 93.3%. Revenue grew 64.1% year-over-year compared to FY 2024. Operating income came in at $125M.

In Q3 2025, RIGEL PHARMACEUTICALS INC reported revenue of $69M and earnings per share (EPS) of $1.55. Net income for the quarter was $28M. Gross margin was 93.2%. Revenue grew 25.6% year-over-year compared to Q3 2024. Operating income came in at $28M.

In Q2 2025, RIGEL PHARMACEUTICALS INC reported revenue of $102M and earnings per share (EPS) of $3.33. Net income for the quarter was $60M. Gross margin was 95.6%. Revenue grew 176.0% year-over-year compared to Q2 2024. Operating income came in at $61M.

Over the past 8 quarters, RIGEL PHARMACEUTICALS INC has demonstrated a growth trajectory, with revenue expanding from $37M to $280M. Investors analyzing RIGL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RIGL Dividend Yield and Income Analysis

RIGEL PHARMACEUTICALS INC (RIGL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RIGL Momentum and Technical Analysis Profile

RIGEL PHARMACEUTICALS INC (RIGL) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RIGL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, RIGEL PHARMACEUTICALS INC (RIGL) ranks #495 out of 838 stocks based on the Blank Capital composite score. This places RIGL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RIGL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RIGL vs S&P 500 (SPY) comparison to assess how RIGEL PHARMACEUTICALS INC stacks up against the broader market across all factor dimensions.

RIGL Next Earnings Date

No upcoming earnings date has been announced for RIGEL PHARMACEUTICALS INC (RIGL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RIGL? — Investment Thesis Summary

The quantitative profile for RIGEL PHARMACEUTICALS INC suggests caution. The quality score of 38/100 flags below-average profitability. The value score of 80/100 suggests attractive pricing relative to fundamentals.

In summary, RIGEL PHARMACEUTICALS INC (RIGL) earns a Reduce rating with a composite score of 41.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RIGL stock.

Related Resources for RIGL Investors

Explore more research and tools: RIGL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RIGL head-to-head with peers: RIGL vs AZN, RIGL vs SLGL, RIGL vs VMD.